Alteryx Joins Forces with Plotly to Enable Data Visualization Throughout the Analytics Lifecycle
Alteryx, Inc., (NYSE: AYX), a leader in self-service data analytics, today announced that it is partnering with Plotly, the preferred data visualization platform for modern data science, to enhance inline “visualytics” within the Alteryx platform. As modern organizations seek to distribute analytics capabilities across a variety of business users, there has been a significant shift towards self-service platforms — and now — for more intuitive visual representations (or inline visualytics) of data as it moves through the analytics pipeline. With this integration, line-of-business analysts can work in a more agile environment that supports sophisticated analytics techniques.
“Increasingly, our customers are asking to visualize and understand their data not just at the conclusion of the analytics process, but throughout the problem-solving journey,” said Dean Stoecker, CEO of Alteryx. “Plotly’s interactive visualization is the ideal technology to match with the Alteryx platform to increase the productivity of analysts during the entire modeling process. Through visual analytics — or, visualytics, as we like to call it — we are making those thrilling discoveries all the more accessible.”
With the Alteryx platform, users have an end-to-end solution to access and discover data assets, utilize powerful dataset creation capabilities, apply statistical and spatial analysis, and visualize data. To date, the Alteryx platform has often been paired with traditional dashboarding solutions to enable visualization. Adding a visualization panel directly into the Alteryx platform is a logical step in creating a unified experience for business analysts. Plotly’s robust charting library and JSON-based architecture makes it an ideal partner for delivering even greater value to customers.
“The Alteryx philosophy of making analytics easier is very much complementary to our mission of empowering users to easily create robust and impactful data visualizations,” said Jack Parmer, CEO of Plotly. “Our open-source, intuitive and interactive technology means that charts, graphs, and other visual assets are as easy to create and share by non-coders, as they are by developers.”
In addition to the Plotly partnership, Alteryx today announced that Ashley Kramer has joined as Vice President of Product Management and will be based in the company’s development facility in Broomfield, Colorado. Kramer brings tremendous knowledge to Alteryx to help scale its product organization, facilitate the development of cloud-based offerings and strengthen strategic technology partnerships. Prior to Alteryx, Kramer was Director of Product Management and Head of Cloud Strategy at Tableau Software, Inc. where she oversaw the vision and development of its SaaS offering. Prior to that, Ashley was Technical Program Manager at Amazon.com, Inc., where she focused on the Kindle product line.
About Alteryx, Inc.
Alteryx (NYSE: AYX) is a leader in self-service data analytics. The Alteryx platform provides analysts with the unique ability to easily prep, blend and analyze all of their data using a repeatable workflow, then deploy and share analytics at scale for deeper insights in hours, not weeks. Analysts love the Alteryx platform because they can connect to and cleanse data from data warehouses, cloud applications, spreadsheets and other sources, easily join this data together, then perform analytics — predictive, statistical and spatial — using the same intuitive user interface, without writing any code.
Visit http://www.alteryx.com or call 1-888-836-4274.
Alteryx is a registered trademark of Alteryx, Inc. All other product and brand names may be trademarks or registered trademarks of their respective owners.
Plotly is the creator of Plotly.js, Dash, PLOTCON, and the fastest growing charting libraries for R and Python. Plotly’s online chart maker at plot.ly is the easiest and fastest way to graph and share D3.js charts online. Plotly customers include Facebook, King Games, Red Hat, S&P Global Market Intelligence and government institutions. Join the data visualization conversation by visiting the Plotly blog, Twitter, LinkedIn and Facebook pages.
Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the partnership with Plotly and its impact on business analysts working with sophisticated analytics techniques. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors including, but not limited to: our ability to integrate Plotly’s work into our platform; our ability to develop and release product and service enhancements and new products and services to respond to rapid technological change in a timely and cost-effective manner; intense and increasing competition in our market; and other general market, political, economic, and business conditions.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme